Report highlights key progress and achievements across three pillars: access to medicines, R&D innovation, and product quality and patient safety 430,000 patients have been treated with Samsung Bioepis’ biosimilars across 40 countries in 2023 In 10 countries, our biosimilars have created social impact worth approximately 2.5 trillion KRW (1.9 billion USD) in 2023 The company [...]
INCHEON, Korea, April 05, 2024 (Korea Bizwire) – Samsung Bioepis Co., Ltd. today announced the initiation of Phase 3 clinical trial for SB27, the company’s proposed biosimilar referencing Keytrudai (pembrolizumab). The Phase 3 clinical trial for SB27 is a randomized, double-blind, parallel group, multicenter studyii to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB27 and Keytruda [...]
Enters into a commercialization agreement for SB17, ustekinumab biosimilar candidate, in Europe and North America Partnership to support Samsung Bioepis pipeline expansion and provide increased access to biosimilars INCHEON, Korea, Sept. 11, 2023 (Korea Bizwire) – Samsung Bioepis Co., Ltd. today announced that it has entered into a commercialization agreement with Sandoz for SB17, [...]
SEOUL, Aug. 2 (Korea Bizwire) — Samsung Bioepis Co., a biosimilar medicine developer under Samsung Group, has been in talks with Biogen Inc. to buy the U.S. biotech firm’s biosimilar business unit, industry sources said Wednesday. Through the deal with the Nasdaq-listed firm, Samsung Bioepis seeks to secure a direct sales network in the United [...]
INCHEON, Korea, June 30 (Korea Bizwire) — Samsung Bioepis Co., Ltd. today released its 2023 sustainability report, highlighting its progress toward building more sustainable and socially responsible practices in research and development (R&D), clinical trials, manufacturing, and supply chain management. “The consequences of the COVID-19 pandemic such as global supply chain disruptions, as well as [...]
INCHEON, Korea, April 17 (Korea Bizwire) — Samsung Bioepis Co., Ltd. today released the first edition of its Biosimilar Market Report which explores latest market trends for all biosimilars commercially available in the United States. The first quarterly report details the most recent price trends of all molecules for which biosimilars have launched, along with [...]
INCHEON, Korea, Nov. 3 (Korea Bizwire) — Samsung Bioepis Co., Ltd. announced the company has won ‘Company of the Year, Asia-Pacific’ at the ‘Global Generics & Biosimilars Awards 2022’ held on November 2, 2022 in Frankfurt, Germany. “It is an honor to receive a prestigious ‘Company of the Year, Asia-Pacific’ award and to be recognized [...]
INCHEON, Korea, Sept. 14 (Korea Bizwire) — Samsung Bioepis Co., Ltd. today announced that it has attained two ISO certifications: ISO 140001 (Environmental Management System) and ISO 50001 (Energy Management System) from Lloyd’s Register Quality Assurance (LRQA), reflecting the company’s ongoing practices and commitment to becoming a sustainable company. “We are delighted to obtain the [...]
SEOUL, July 20 (Korea Bizwire) — South Korean biopharmaceutical firm Samsung Bioepis Co. was in the process of acquiring regulatory approval from European and South Korean drug authorities for SB12, a paroxysmal nocturnal hemoglobinuria (PNH) treatment biosimilar candidate, industry sources said Wednesday. The company has submitted approval applications for SB12, a more affordable version of [...]
SEOUL, April 20 (Korea Bizwire) — Samsung Biologics Co., the biotech arm of South Korea’s Samsung Group, said Wednesday it has completed the first payment to acquire the U.S. drugmaker’s entire stake in Samsung Bioepis. Earlier, Samsung Biologics reached a deal with Biogen to purchase the U.S. drugmaker’s entire stake in Samsung Bioepis for US$2.3 [...]